What is the current Companion Cancer Diagnostics market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Companion Cancer Diagnostics market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Companion Cancer Diagnostics market?

Increasing cancer prevalence and technological advancements drive the market.

What are the major challenges facing the Companion Cancer Diagnostics market?

High development costs and regulatory hurdles are major challenges.

Which regions are expected to lead the Companion Cancer Diagnostics market?

North America and Europe are expected to dominate the market.

Who are the top companies in the Companion Cancer Diagnostics market?

Major players include Roche, Abbott, and Illumina.

What are the future opportunities in the Companion Cancer Diagnostics market?

Emerging markets and innovative technologies offer future growth opportunities.

How will technology impact the Companion Cancer Diagnostics market?

Advances in genomics and artificial intelligence will drive market growth.

What is the current regulatory landscape for the Companion Cancer Diagnostics market?

Stringent regulations and approvals are required for market entry.

What is the future outlook for the Companion Cancer Diagnostics market size?

The market is expected to reach USD 2.5 billion by 2033.

Which Companies Lead the Companion Cancer Diagnostics Market in 2026?

Companion Cancer Diagnostics by Type (/> Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gastric Cancer), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Companion Cancer Diagnostics Market Overview

The Companion Cancer Diagnostics market refers to the industry involved in developing and marketing diagnostic tests used in conjunction with cancer therapies. As the Companion Cancer Diagnostics market size is projected to reach $8.9 billion by 2026, the growth outlook and market forecast indicate a promising future, with the industry expected to expand significantly over the forecast period. The scope of this market encompasses various cancer diagnostics, including next-generation sequencing, polymerase chain reaction, and immunohistochemistry, among others. The current market size is approximately $4.5 billion, with a growth forecast of 12.1% CAGR from 2026 to 2033, driven by macro drivers such as increasing cancer prevalence, advancements in diagnostic technologies, and rising demand for personalized medicine.

Loading chart…

Key forces shaping the industry include technology shifts, such as the adoption of artificial intelligence and machine learning in diagnostic testing, regulations, such as the increasing need for regulatory approvals, and consumer behavior, with patients seeking more personalized and targeted therapies. The largest region in the Companion Cancer Diagnostics market is North America, while the fastest-growing region is Asia-Pacific, driven by increasing healthcare expenditure and a rising demand for cancer diagnostics. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends and developments to capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	32.36 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	F. Hoffmann-La Roche; Agilent Technologies; QIAGEN; Abbott Laboratories; Almac Group; Danaher Corporation; bioMérieuxSA; Myriad Genetics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Companion Cancer Diagnostics market is poised for significant growth, driven by increasing demand for personalized medicine and advancements in diagnostic technologies. The Companion Cancer Diagnostics market size is expected to expand rapidly, with a substantial growth forecast over the next five years.

Growth Drivers2 items

Advances in next-generation sequencing and liquid biopsy technologies are enabling the development of more accurate and minimally invasive diagnostic tests, driving growth in the Companion Cancer Diagnostics market.

Increasing adoption of precision medicine approaches in cancer treatment is fueling demand for companion diagnostics, contributing to the growth forecast of the market.

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the Companion Cancer Diagnostics market, restraining market growth.

Reimbursement challenges and pricing pressures are affecting the profitability of established players, further constraining the Companion Cancer Diagnostics market size.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America present significant opportunities for growth, driven by increasing cancer incidence and improving healthcare infrastructure, supporting the growth forecast of the Companion Cancer Diagnostics market.

Partnerships between diagnostic companies and pharmaceutical firms can facilitate the development of companion diagnostics and expand market reach, contributing to the Companion Cancer Diagnostics market size.

Challenges2 items

The complex and ever-evolving landscape of cancer biology and treatment options poses significant challenges for the development of effective companion diagnostics, affecting the Companion Cancer Diagnostics market.

Ensuring standardization and harmonization of diagnostic tests across different regions and healthcare systems remains a major challenge, impacting the growth forecast of the market.

Market Segmentation

Loading chart…

The Companion Cancer Diagnostics market can be segmented by Type, which contains various subtypes. This segmentation is crucial in understanding the Companion Cancer Diagnostics segmentation and its contribution to the overall market size. The subtypes within the Type segment include different diagnostic tests and tools used to detect and monitor cancer.

Analyzing the Type segment is essential in identifying the dominant subtypes driving the market growth. By understanding the market taxonomy and the various subtypes within the Type segment, stakeholders can develop targeted strategies to capitalize on emerging opportunities. The Type segment contributes significantly to the overall Companion Cancer Diagnostics market size, and its subtypes are expected to witness varying growth rates.

Companion Cancer Diagnostics Segmentation Breakdown6 items

Type

/> Breast Cancer

Lung Cancer

Colorectal Cancer

Melanoma

Gastric Cancer

Regional Insights

Loading chart…

The Companion Cancer Diagnostics market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The Asia Pacific region is anticipated to be the fastest-growing region, driven by increasing adoption of advanced cancer diagnostics, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high infrastructure development, and a large patient population. In Europe, drivers include a strong regulatory framework, increasing demographics of the aging population, and a high adoption rate of innovative diagnostics. The Asia Pacific region is driven by a large and growing patient population, increasing investments in healthcare, and a rising ecosystem maturity. Latin America and Middle East & Africa are driven by growing demand for cancer diagnostics, improving infrastructure, and increasing adoption of advanced technologies.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by government initiatives and private investments in healthcare. North America and Europe will continue to dominate the market, driven by their mature ecosystems and high adoption rates. Latin America and Middle East & Africa will experience moderate growth, driven by improving infrastructure and increasing demand for cancer diagnostics.

Competitive Landscape

The Companion Cancer Diagnostics market exhibits a moderately consolidated structure, driven by a mix of global players and local companies. The Companion Cancer Diagnostics competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to dominate the market, while local companies focus on regional expansion and customization to gain a competitive edge.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must focus on technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategies to navigate the market:

F. Hoffmann-La Roche: regional expansion

Agilent Technologies: innovation pipeline

QIAGEN: premium pricing

Abbott Laboratories: vertical integration

Almac Group: local manufacturing

Danaher Corporation: OEM tie-ups

Key Companion Cancer Diagnostics Companies8 items

F. Hoffmann-La Roche

Agilent Technologies

QIAGEN

Abbott Laboratories

Almac Group

Danaher Corporation

bioMérieuxSA

Myriad Genetics

Market Ecosystem

The Companion Cancer Diagnostics ecosystem spans upstream, midstream, and downstream activities, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of diagnostic products and services. The ecosystem boundaries are defined by the interactions between these participants, influencing how value flows from raw materials to end users.

Technology providers — develop diagnostic technologies

OEMs / manufacturers — produce diagnostic equipment

System integrators / EPCs — integrate diagnostic systems

Distributors / channel partners — supply diagnostic products

Service providers / after-sales — offer maintenance and support

End users / buyers — utilize diagnostic products and services

Regulators/standards bodies — establish diagnostic standards and approvals

In the Companion Cancer Diagnostics ecosystem, control points are primarily held by regulators and standards bodies, influencing adoption through approvals and standards. Dependency risks arise from input constraints, such as access to raw materials, and approvals from regulatory bodies. Switching costs and partnerships also play a crucial role, as companies may face significant costs when changing suppliers or partners. Furthermore, interoperability requirements can impact the ecosystem, particularly in regions with diverse regulatory frameworks, highlighting the need for a thorough value chain analysis to navigate these complexities.

Recent Industry Insights

The Companion Cancer Diagnostics market has witnessed significant developments over the last 12-18 months, shaping the industry's future. Recent partnerships, such as collaborations between pharmaceutical companies and diagnostic firms, have been instrumental in driving innovation. Notable mergers and acquisitions have also taken place, leading to consolidation and expansion of product portfolios. Furthermore, several product launches have introduced advanced technologies, enhancing the accuracy and efficiency of cancer diagnostics.

These developments are in line with the evolving Companion Cancer Diagnostics industry trends, which emphasize the importance of precision medicine and personalized treatment. Regulatory changes have also supported the growth of the market, with authorities approving new diagnostic tests and therapies. Additionally, there has been a notable shift in consumer and enterprise trends, with increased focus on early cancer detection and prevention. Funding rounds and expansions have provided the necessary financial backing for companies to invest in research and development, driving further innovation in the field.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Companion Cancer Diagnostics market. The market attractiveness is driven by the increasing demand for personalized medicine and the need for effective cancer treatment options. The competitive intensity is moderate, with key players focusing on innovation and strategic partnerships. The long-term outlook for the Companion Cancer Diagnostics market outlook is positive, with a growing emphasis on precision medicine and targeted therapies.

The innovation landscape is rapidly evolving, with advancements in next-generation sequencing and artificial intelligence. However, the demand–supply balance is a key risk factor, as the market faces challenges in meeting the growing demand for diagnostic tests. Other key risk factors include regulatory changes and reimbursement pressures. Overall, the Companion Cancer Diagnostics market is expected to experience significant growth, driven by the increasing adoption of personalized medicine approaches.

11 items

1. Executive Summary

2. Companion Cancer Diagnostics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Companion Cancer Diagnostics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Companion Cancer Diagnostics Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Breast Cancer

6.1.2. Lung Cancer

6.1.3. Colorectal Cancer

6.1.4. Melanoma

6.1.5. Gastric Cancer

6.2. Global Companion Cancer Diagnostics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Companion Cancer Diagnostics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Companion Cancer Diagnostics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Companion Cancer Diagnostics Market Competition by Key Manufacturers

8.1. Global Companion Cancer Diagnostics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Companion Cancer Diagnostics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. F. Hoffmann-La Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Agilent Technologies

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. QIAGEN

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbott Laboratories

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Almac Group

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Danaher Corporation

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. bioMérieuxSA

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Myriad Genetics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

20 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Companion Cancer Diagnostics Market

Figure 4: Global Companion Cancer Diagnostics Market: Drivers

Figure 5: Global Companion Cancer Diagnostics Market: Challenges

Figure 6: Global Companion Cancer Diagnostics Market: Trends

Figure 7: Global Companion Cancer Diagnostics Market: Opportunity

Figure 8: Global Companion Cancer Diagnostics Market: Restraint

Figure 9: Global Companion Cancer Diagnostics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Companion Cancer Diagnostics Market Value (USD Million) By Region

Figure 13: Global Companion Cancer Diagnostics Market Share (%) By: Regions (2024)

Figure 14: Top 5 Manufacturers

Figure 15: Top 3 Manufacturers

Figure 16: Global Market Value (USD Million) (2025-2032) By Type

Figure 17: Global Market Share (%) By Type (2032)

Figure 18: Global Companion Cancer Diagnostics Market Value (USD Million) By Region

Figure 19: Global Companion Cancer Diagnostics Market Share (%) By: Regions (2032)

Figure 20: Data Triangulation

List of Tables

54 items

Table 1: Market Segmentation Analysis

Table 2: Global Companion Cancer Diagnostics Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Companion Cancer Diagnostics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 4: Global Market Value (USD Million) (2020-2024) By Type

Table 5: Global Market Share (%) By Type (2024)

Table 6: Global Companion Cancer Diagnostics Market Value (USD Million) By Region

Table 7: Global Companion Cancer Diagnostics Market Share (%) By Region

Table 8: North America Market Value (USD Million) (2020-2024) By Country

Table 9: North America Market Value (USD Million) (2020-2024) By Type

Table 10: Europe Market Value (USD Million) (2020-2024) By Country

Table 11: Europe Market Value (USD Million) (2020-2024) By Type

Table 12: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 13: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 14: South America Market Value (USD Million) (2020-2024) By Country

Table 15: South America Market Value (USD Million) (2020-2024) By Type

Table 16: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 17: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 18: Global Companion Cancer Diagnostics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 19: Global Companion Cancer Diagnostics Market: Profiled Players Head Office And Area Served

Table 20: Key Players Global Companion Cancer Diagnostics Market:

Table 21: Mergers & Acquisitions, Expansion Plans

Table 22: F. Hoffmann-La Roche Basic Information And Sales Area

Table 23: F. Hoffmann-La Roche. Products Portfolio

Table 24: Agilent Technologies Basic Information And Sales Area

Table 25: Agilent Technologies. Products Portfolio

Table 26: QIAGEN Basic Information And Sales Area

Table 27: QIAGEN. Products Portfolio

Table 28: Abbott Laboratories Basic Information And Sales Area

Table 29: Abbott Laboratories. Products Portfolio

Table 30: Almac Group Basic Information And Sales Area

Table 31: Almac Group. Products Portfolio

Table 32: Danaher Corporation Basic Information And Sales Area

Table 33: Danaher Corporation. Products Portfolio

Table 34: bioMérieuxSA Basic Information And Sales Area

Table 35: bioMérieuxSA. Products Portfolio

Table 36: Myriad Genetics Basic Information And Sales Area

Table 37: Myriad Genetics. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Type

Table 39: Global Market Share (%) By Type (2032)

Table 40: Global Companion Cancer Diagnostics Market Value (USD Million) By Region

Table 41: Global Companion Cancer Diagnostics Market Share (%) By Region (2025-2032)

Table 42: North America Market Value (USD Million) (2025-2032) By Country

Table 43: North America Market Value (USD Million) (2025-2032) By Type

Table 44: Europe Market Value (USD Million) (2025-2032) By Country

Table 45: Europe Market Value (USD Million) (2025-2032) By Type

Table 46: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 47: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 48: South America Market Value (USD Million) (2025-2032) By Country

Table 49: South America Market Value (USD Million) (2025-2032) By Type

Table 50: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 51: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 52: Research Programs/Design For This Report

Table 53: Key Data Information From Secondary Sources

Table 54: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Companion Cancer Diagnostics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	32.36 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	F. Hoffmann-La Roche; Agilent Technologies; QIAGEN; Abbott Laboratories; Almac Group; Danaher Corporation; bioMérieuxSA; Myriad Genetics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing adoption of precision medicine approaches in cancer treatment is fueling demand for companion diagnostics, contributing to the growth forecast of the market.

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the Companion Cancer Diagnostics market, restraining market growth.

Reimbursement challenges and pricing pressures are affecting the profitability of established players, further constraining the Companion Cancer Diagnostics market size.

Opportunities2 items

Challenges2 items

Ensuring standardization and harmonization of diagnostic tests across different regions and healthcare systems remains a major challenge, impacting the growth forecast of the market.

Market Segmentation

Loading chart…

Companion Cancer Diagnostics Segmentation Breakdown6 items

Type

/> Breast Cancer

Lung Cancer

Colorectal Cancer

Melanoma

Gastric Cancer

Regional Insights

Loading chart…

Competitive Landscape

F. Hoffmann-La Roche: regional expansion

Agilent Technologies: innovation pipeline

QIAGEN: premium pricing

Abbott Laboratories: vertical integration

Almac Group: local manufacturing

Danaher Corporation: OEM tie-ups

Key Companion Cancer Diagnostics Companies8 items

F. Hoffmann-La Roche

Agilent Technologies

QIAGEN

Abbott Laboratories

Almac Group

Danaher Corporation

bioMérieuxSA

Myriad Genetics

Market Ecosystem

Technology providers — develop diagnostic technologies

OEMs / manufacturers — produce diagnostic equipment

System integrators / EPCs — integrate diagnostic systems

Distributors / channel partners — supply diagnostic products

Service providers / after-sales — offer maintenance and support

End users / buyers — utilize diagnostic products and services

Regulators/standards bodies — establish diagnostic standards and approvals

Recent Industry Insights

Analyst Overview

Table of Contents